{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+Pediatric+ALL&page=2", "query": { "condition": "Relapsed Pediatric ALL", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+Pediatric+ALL&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T09:45:13.129Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00189436", "title": "Effect of Nebulized Budesonide and Oral Corticosteroids on Wheezing Episode Relapse in Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Nebulized Budesonide", "type": "DRUG" }, { "name": "Usual care (albuterol with or without oral steroid)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Deborah Gentile", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "8 Years", "sex": "ALL", "summary": "1 Year to 8 Years" }, "enrollment_count": 61, "start_date": "2003-03", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2021-02-01", "last_synced_at": "2026-05-22T09:45:13.129Z", "location_count": 2, "location_summary": "Bellevue, Pennsylvania • Pittsburgh, Pennsylvania", "locations": [ { "city": "Bellevue", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00189436" }, { "nct_id": "NCT00098865", "title": "Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Central Nervous System Tumor, Pediatric", "Neuroblastoma" ], "interventions": [ { "name": "temozolomide", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 15, "start_date": "2002-09", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2014-10-07", "last_synced_at": "2026-05-22T09:45:13.129Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00098865" }, { "nct_id": "NCT04634357", "title": "ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hepatoblastoma", "Hepatocellular Carcinoma (HCC)", "Liver Neoplasms", "Metastatic Liver Cancer", "Liver Cancer", "HEMNOS" ], "interventions": [ { "name": "ET140203 T Cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eureka Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 15, "start_date": "2022-07-19", "completion_date": "2028-01-31", "has_results": false, "last_update_posted_date": "2025-04-09", "last_synced_at": "2026-05-22T09:45:13.129Z", "location_count": 2, "location_summary": "San Francisco, California • Boston, Massachusetts", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04634357" }, { "nct_id": "NCT01523977", "title": "Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "PEG-Asparaginase", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Dexrazoxane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "18 Months to 21 Years" }, "enrollment_count": 22, "start_date": "2011-11", "completion_date": "2018-11", "has_results": false, "last_update_posted_date": "2024-07-18", "last_synced_at": "2026-05-22T09:45:13.129Z", "location_count": 8, "location_summary": "San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01523977" }, { "nct_id": "NCT06466395", "title": "A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Refractory Acute Leukemia", "Relapsed Acute Leukemia", "Undifferentiated Leukemia", "Bi-Phenotypic Leukemia" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Hyper-CVAD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 22, "start_date": "2025-02-18", "completion_date": "2031-12-31", "has_results": false, "last_update_posted_date": "2026-03-09", "last_synced_at": "2026-05-22T09:45:13.129Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06466395" }, { "nct_id": "NCT03495921", "title": "A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ewing Sarcoma", "Ewing Family of Tumors", "Ewing's Tumor Metastatic", "Ewing's Sarcoma Metastatic", "Ewing's Tumor Recurrent", "Rare Diseases", "Sarcoma", "Neoplasms, Connective and Soft Tissue", "Neoplasms by Histologic Type", "Neoplasms, Bone Tissue", "Neoplasms, Connective Tissue", "Sarcoma, Ewing", "Neoplasms" ], "interventions": [ { "name": "Vigil", "type": "BIOLOGICAL" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Gradalis, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 32, "start_date": "2018-08-21", "completion_date": "2022-01-20", "has_results": true, "last_update_posted_date": "2023-04-26", "last_synced_at": "2026-05-22T09:45:13.129Z", "location_count": 15, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Jacksonville, Florida + 12 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03495921" }, { "nct_id": "NCT00698009", "title": "Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Natural Killer Cell Infusion", "type": "BIOLOGICAL" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1, "start_date": "2008-06", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2020-09-24", "last_synced_at": "2026-05-22T09:45:13.129Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00698009" }, { "nct_id": "NCT04145700", "title": "CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Synovial Sarcoma" ], "interventions": [ { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "29 Years", "sex": "ALL", "summary": "12 Months to 29 Years" }, "enrollment_count": 23, "start_date": "2020-03-04", "completion_date": "2023-02-23", "has_results": true, "last_update_posted_date": "2023-09-13", "last_synced_at": "2026-05-22T09:45:13.129Z", "location_count": 27, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04145700" }, { "nct_id": "NCT00372619", "title": "Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "clofarabine", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 74, "start_date": "2007-03", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2017-06-05", "last_synced_at": "2026-05-22T09:45:13.129Z", "location_count": 74, "location_summary": "Birmingham, Alabama • Downey, California • Long Beach, California + 65 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Downey", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Madera", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00372619" }, { "nct_id": "NCT02435849", "title": "Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-cell Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "CTL019", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "25 Years", "sex": "ALL", "summary": "Up to 25 Years" }, "enrollment_count": 80, "start_date": "2015-04-08", "completion_date": "2022-11-17", "has_results": true, "last_update_posted_date": "2024-02-13", "last_synced_at": "2026-05-22T09:45:13.129Z", "location_count": 11, "location_summary": "Los Angeles, California • Stanford, California • Atlanta, Georgia + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02435849" } ] }